Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic  Evaluation in the Treatment of Type 2  Diabetes Mellitus

Santoleri, Fiorenzo; Sorice, Paola; Lasala, Ruggero; Costantini, Alberto

doi:10.4236/pp.2014.54040

Cited by 1 publication

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[106] In a 12-month follow-up study of treatment adherence, proportion of days covered (PDC) was 71.0% and medication possession ratio (MPR) was 76.0% in patients with T2DM ( N = 881) receiving canagliflozin. The corresponding median PDC was 83.0% and MPR value was 88.0%, indicating good treatment adherence with canagliflozin 300 mg.[107] Furthermore, persistence with AHAs is an important predictor of outcomes in these patients.…”

Section: Treatment Adherence and Persistence Of Canagliflozin 300 Mgmentioning

confidence: 99%

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Kumar

Ghosh

Canovatchel

et al. 2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic armamentarium of glucose-lowering drugs. This review summarizes findings from different clinical and observational studies of canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose, thereby increasing urinary glucose excretion in patients with T2DM. Canagliflozin 300 mg has been shown to be effective in lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions in body weight and blood pressure and has a low risk of causing hypoglycemia, when not used in conjunction with insulin and insulin secretagogues. Canagliflozin 300 mg was generally well tolerated in clinical studies. The most frequently reported adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis, and volume depletion-related events.

show abstract

Section: Treatment Adherence and Persistence Of Canagliflozin 300 Mgmentioning

confidence: 99%

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Kumar

Ghosh

Canovatchel

et al. 2017

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus

Cited by 1 publication

References 39 publications

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About